Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/clk2-blockade-modulates-alternative-splicing-compromising-myc-driven-0D93WS5fJ0
References (13)
-
S. Bonnal, Luisa Vigevani, J. Valcárcel (2012)
The spliceosome as a target of novel antitumour drugsNature Reviews Drug Discovery, 11
-
M. Muraki, B. Ohkawara, T. Hosoya, H. Onogi, Jun Koizumi, Tomonobu Koizumi, Kengo Sumi, Jun-ichiro Yomoda, M. Murray, H. Kimura, K. Furuichi, H. Shibuya, A. Krainer, Masaaki Suzuki, M. Hagiwara (2004)
Manipulation of Alternative Splicing by a Newly Developed Inhibitor of Clks*Journal of Biological Chemistry, 279
-
(2018)
License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited -
Taku Yoshida, J. Kim, Kristopher Carver, Ying Su, S. Weremowicz, Laura Mulvey, S. Yamamoto, C. Brennan, S. Mei, Henry Long, Jun Yao, K. Polyak (2015)
CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer.Cancer research, 75 7
-
Savitha Sridharan, A. Basu (2011)
S6 kinase 2 promotes breast cancer cell survival via Akt.Cancer research, 71 7
-
Changwen Zhang, Chunyang Yin, Lei Wang, Shuping Zhang, Yi Qian, Juan Ma, Zhihong Zhang, Yong Xu, Sijin Liu (2014)
HSPC111 Governs Breast Cancer Growth by Regulating Ribosomal BiogenesisMolecular Cancer Research, 12
-
Shinsuke Araki, R. Dairiki, Yusuke Nakayama, Aiko Murai, R. Miyashita, Misa Iwatani, T. Nomura, O. Nakanishi (2015)
Inhibitors of CLK Protein Kinases Suppress Cell Growth and Induce Apoptosis by Modulating Pre-mRNA SplicingPLoS ONE, 10
-
H. Dvinge, Eunhee Kim, O. Abdel-Wahab, R. Bradley (2016)
RNA splicing factors as oncoproteins and tumour suppressorsNature Reviews Cancer, 16
-
(2018)
Anti-tumor efficacy -
Qiang Liu, Na Liu, S. Zang, Heng Liu, Pin Wang, C. Ji, Xiulian Sun (2014)
Tumor Suppressor DYRK1A Effects on Proliferation and Chemoresistance of AML Cells by Downregulating c-MycPLoS ONE, 9
-
Kenichi Iwai, M. Yaguchi, Kazuho Nishimura, Yukiko Yamamoto, T. Tamura, Daisuke Nakata, R. Dairiki, Yoichi Kawakita, R. Mizojiri, Yoshiteru Ito, Moriteru Asano, Hironobu Maezaki, Yusuke Nakayama, Misato Kaishima, K. Hayashi, Mika Teratani, Shuichi Miyakawa, Misa Iwatani, M. Miyamoto, M. Klein, W. Lane, G. Snell, R. Tjhen, Xingyue He, S. Pulukuri, T. Nomura (2018)
Anti‐tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC‐dependent vulnerabilityEMBO Molecular Medicine, 10
-
T. Hsu, L. Simon, N. Neill, Richard Marcotte, Azin Sayad, C. Bland, G. Echeverria, T. Sun, S. Kurley, S. Tyagi, Kristen Karlin, Rocio Vidana, Jessica Hartman, Alexander Renwick, K. Scorsone, R. Bernardi, S. Skinner, Antrix Jain, Mayra Orellana, Chandraiah Lagisetti, I. Golding, S. Jung, J. Neilson, X. Zhang, T. Cooper, T. Webb, B. Neel, C. Shaw, T. Westbrook (2015)
The spliceosome is a therapeutic vulnerability in MYC-driven cancerNature, 525
-
A. Butt, A. Butt, C. Sergio, Claire Inman, Luke Anderson, C. McNeil, A. Russell, Marco Nousch, T. Preiss, A. Biankin, A. Biankin, ROBERT Sutherland, ROBERT Sutherland, E. Musgrove, E. Musgrove, E. Musgrove (2008)
The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcomeBreast Cancer Research : BCR, 10
- Publisher
- Wiley
- Copyright
- © 2018 EMBO
- ISSN
- 1757-4676
- eISSN
- 1757-4684
- DOI
- 10.15252/emmm.201809213
- Publisher site
- See Article on Publisher Site
Abstract
Journal
Embo Molecular Medicine – Wiley
Published: Jan 1, 2018